Landgren O, Hultcrantz M, Diamond B, et al. - Researchers undertook this nonrandomized clinical trial to investigate whether carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy is safe and effective in patients with newly diagnosed multiple myeloma, in the absence of high-dose melphalan chemotherapy and autologous hemopoietic cell transplant. Among 41 evaluable patients [median age, 59 years; range, 30-70 years); 25 (61%) were female, and 20 (49%) with high-risk multiple myeloma], a median follow-up of 20.3 months was conducted from the initiation of therapy. A total of 29 patients achieved the primary endpoint (minimal residual disease negativity), and thus the trial was deemed successful. Treatment-related serious adverse events occurred in 8 patients, no deaths occurred. Findings showed that high rates of minimal residual disease negativity as well as high rates of progression-free survival were conferred by carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy in patients with newly diagnosed multiple myeloma.